A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).

Trial Details

NCT ID
NCT06934044
Phase
PHASE1
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Cevostamab
  • Tocilizumab
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Nanchang, China|28.68396,115.85306
  • Wenzhou, China|27.99942,120.66682
  • Wuhan, China|30.58333,114.26667

Key Eligibility Criteria

  • Documented diagnosis of MM based on standard International Myeloma Working Group (IMWG) criteria
  • Evidence of progressive disease based on investigators determination of response by IMWG criteria on or after their last dosing regimen
  • Current relapsed or refractory (R/R) disease status
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →